Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome.

Abstract

Available animal and cell line models have suggested that specific therapeutics might be effective in treating Middle East respiratory syndrome (MERS). We conducted a systematic review of evidence for treatment with pharmacologic and supportive therapies. We developed a protocol and searched 5 databases for studies describing treatment of MERS and deaths in MERS patients. Risk of bias (RoB) was assessed by using ROBINS-I tool. We retrieved 3,660 unique citations; 20 observational studies met eligibility, and we studied 13 therapies. Most studies were at serious or critical RoB; no studies were at low RoB. One study, at moderate RoB, showed reduced mortality rates in severe MERS patients with extracorporeal membrane oxygenation; no other studies showed a significant lifesaving benefit to any treatment. The existing literature on treatments for MERS is observational and at moderate to critical RoB. Clinical trials are needed to guide treatment decisions.

• Authors: Taylor Kain, Patrick J Lindsay, Neill K J Adhikari, Yaseen M Arabi, Maria D Van Kerkhove, Robert A Fowler
• Journal: Emerging infectious diseases (Emerg Infect Dis) Vol. 26 Issue 6 Pg. 1102-1112 (Jun 2020) ISSN: 1080-6059 [Electronic] United States
• PMID: 32213260 (Publication Type: Journal Article, Systematic Review)

Chemical References

• Antiviral Agents

Topics

• Antiviral Agents (therapeutic use)
• Coronavirus Infections (drug therapy, virology)
• Humans
• Middle East Respiratory Syndrome Coronavirus